Shares

Here you will find information on Sartorius preference shares (SRT3) and Sartorius ordinary shares (SRT).

Click here for Sartorius Stedim Biotech shares (DIM)

Stock Chart

Stock Chart

Shares Overview

ISIN

Ordinary share: DE0007165607 | Preference share: DE0007165631 

SE Code

Ordinary share: SRT | Preference share: SRT3 

Capital stock

74,880,000 euros

Number of shares outstanding
(excluding treasury shares)

Ordinary shares: 34,230,928 | Preference shares: 34,807,268

Number of shares
(including treasury shares)

74,880,000 no-par individual share certificates; 
thereof Ordinary shares: 37,440,000 | Preference shares: 37,440,000

Market Segment

Prime Standard 

Indices

DAX | TecDAX | MSCI Germany Index | CDAX | Prime All-Share-Index | Technology All Share-Index | NISAX20 | STOXX Europe 600 | DAX 50 ESG

Market places

XETRA | Frankfurt Main | Hanover | Hamburg | Berlin | Munich | Düsseldorf | Stuttgart | Tradegate

Designated Sponsors

Oddo Seydler Bank AG | M.M. Warburg & Co.

First trading day

July, 10, 1990; Issue price: Ordinary share DM 710 | 
Preference share DM 610

Post IPO Activities

04.06.1998:

Capital increase by DM 11 million to DM 36 million by preference share at the issue price of DM 630

13.12.1999:

Conversion of DM 50 par value shares to individual share certificate with an accounting par value of 1 euro at a ratio of 1:26 (stock split)

13.06.2016:

Capital increase by use of retained earnings for carrying out a stock split at a ratio of 1:4

09.02.2024:

Placement of 613,497 preference shares (the “Placement Preference Shares”) held in treasury with the exclusion of existing shareholders’ subscription rights (the “Treasury Share Placement”) at a price of 326.00 euros per share 

Paying and exchange agent for Sartorius AG shares

Commerzbank AG (Neue Börsenstraße 1, 60487 Frankfurt am Main, Germany)

Sartorius AG is currently covered by 28 sell-side analysts. The following list  shows banks and securities firms that publish regular research reports on Sartorius´s preference shares. 

InstitutionAnalyst
AlphaValueVirendra Chauhan
Bank of AmericaCharlie Haywood
Barclays Charles Pitman-King
Berenberg Sam England
BernsteinDelphine Le Louet
Deutsche BankFalko Friedrichs
DZ BankSven Kürten
EQUI.TSThomas J. Schießle
ExaneOdysseas Manesiotis
Goldman SachsJames Quigley
Guggenheim SecuritiesSubbu Nambi 
HSBCShubhangi Gupta
Jefferies James Vane-Tempest
JP MorganRichard Vosser
Kepler ChevreuxOliver Reinberg
KeyBancPaul Knight
LBBWVolker Stoll
MetzlerAlexander Neuberger
Morgan StanleyThibault Boutherin
Morningstar Max Jousma
mwb Research Harald Hof
Nephron Tom DeBourcy
ODDO BHFOliver Metzger
RBC Capital Markets Charles Weston  
Redburn AtlanticEd Ridley-Day
Stifel Dylan Van Haaften
UBSMatthew Weston 
Wolfe Research Doug Schenkel

Disclaimer

Sartorius does not provide consensus data on its own website but redirects to Vara website.

Sartorius AG is covered by various German and international financial analysts, who provide their own research analyses and earnings estimates in respect of Sartorius AG. The most recent consensus is collected and provided by Vara Research and contains evaluations and estimates of these financial analysts. The consensus contains forward-looking statements, which are based on the current estimates and assumptions exclusively given by the participating analysts. Forward-looking statements are not to be understood as in any way guaranteeing that those expectations will turn out to be accurate. Future performance and the results achieved by Sartorius AG and its affiliated companies depend on a number of risks and uncertainties such as the future economic and market environment. Most of these factors are outside Sartorius’ control and cannot be accurately estimated in advance.

The consensus is not compiled by Sartorius, and Sartorius does not control, change or censor it. Therefore, Sartorius shall not be liable for any deviation between the consensus and the company’s financial results. The development of the consensus by Vara Research is independent and not influenced by Sartorius.

Sartorius solely provides links to Vara Research GmbH website, but it does not make any recommendations of its own. The publication of this information does not imply that Sartorius makes any representations, warranties, or accepts or confirms such information, conclusions, or recommendations. The company therefore assumes no responsibility for the accuracy or completeness of these estimates and does not undertake to supervise, update or revise them, or even to comment or correct them. This is a complete autonomous application of Vara Research and Sartorius assumes no action, nor bears any responsibility regarding the information contained.

Data published by Vara Research remains under the entire Vara Research responsibilities. By accessing these Vara Research’s data, you acknowledge that you have been made aware by Sartorius of the risks involved in using Vara Research’s data.

You, hereby agree to release Sartorius AG, its subsidiaries and affiliates, their directors, officers, and other representatives from any and all liabilities, whether directly or by way of indemnification, and you waive any and all claims for any direct and/or indirect, consequential damages, of any nature whatsoever (including in particular financial losses) arising directly or indirectly, from the access and use of Vara Research’s data and Vara Research’s website.

You are now leaving the Sartorius website to go to an independent third-party website.

By clicking the “I agree” button below, you will be transferred to a webpage which contains information that is maintained by Vara Research. The service presents consensus estimates and recommendations that are calculated and compiled regularly and independently by Vara Research. Sartorius has no control over the linked webpage and its content.

The consensus is collected and provided by Vara Research and can be found by clicking on the “I agree” button below.

By clicking to the “i agree” button below, you confirm your understanding of the above disclaimer and agree to all of its terms.


I agree

Shareholder Structure

Sartorius AG’s issued capital comprises 37,440,000 million ordinary shares and the same number of preference shares, each with a calculated par value of €1 per share. Some of both classes of share are held by the company itself. Minus these treasury shares, the number of ordinary shares outstanding is 34,230,928 and the number of preference shares outstanding is 34,807,268.

Sartorius AG Preference Shares (SRT3)

in %, related to ~34.8 million shares outstanding

According to the information currently available, around 28 % of the preference shares outstanding are held by Bio-Rad Laboratories Inc. and 72 % are in free float.

Sartorius AG Ordinary Shares (SRT)

in %, related to ~34.2 million shares outstanding

A good 55 % of the ordinary shares outstanding are under the management of an executor. According to the most recent information available, the U.S. company Bio-Rad Laboratories Inc. holds around 38 % of the ordinary shares outstanding. To our knowledge, the remaining approximately 7 % are in free float.

Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. These reporting obligations and own disclosures refer only to voting shares and not to non-voting preference shares. For this reason, the shareholder structure disclosed for Sartorius preference shares does not contain any detailed information beyond the company’s treasury shares.

icon-e-mail
Investors Contact